Sugi Predict

Sugi Predict / Compounds / SCHEMBL7189282

SCHEMBL7189282

SCHEMBL7189282

Cc1cc(C(C)(C)C)cc(C)c1C(=O)[PH](=O)c1c(Cl)cc(Cl)c(C(=O)c2ccccc2)c1Cl

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.34
▸ TP53 P04637 3/20 0.33
▸ RXRB P28702 2/20 0.33
▸ RXRA P19793 1/20 0.33
▸ GLA P06280 2/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ PPARG P37231 1/20 0.33
▸ NR1H4 Q96RI1 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ ITGA1 P56199 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ ATM Q13315 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ KCNK9 Q9NPC2 1/20 0.32
▸ SRD5A2 P31213 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182322 0.91 TP53 (0.34) LMNATP53RXRBRXRAGLA
SCHEMBL7188750 0.89 MEN1 (0.39) LMNATP53ALDH1A1HPGDGAA
SCHEMBL7175334 0.89 TP53 (0.36) LMNATP53RXRBALDH1A1PPARG
SCHEMBL7174653 0.88 LMNA (0.38) LMNAALDH1A1GAAMAPTTDP1
SCHEMBL7182634 0.87 LMNA (0.36) LMNARXRBRXRAGLAALDH1A1
SCHEMBL7182791 0.85 TP53 (0.34) LMNATP53ALDH1A1HPGDGAA
SCHEMBL7178025 0.84 KMT2A (0.34) LMNATP53ALDH1A1HPGDMAPT
SCHEMBL7174760 0.83 LMNA (0.39) LMNAALDH1A1GAAMAPTTDP1
SCHEMBL7181244 0.82 TNFRSF1A (0.35) LMNARXRBRXRAALDH1A1HPGD
SCHEMBL7190429 0.82 LMNA (0.38) LMNARXRBRXRAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 LMNA 3241/4885TP53 3575/4885RXRB 3027/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 LMNA 3247/4885TP53 3524/4885RXRB 3240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.